Now in a tug of war with Lundbeck, Alkermes could either lose out on a marketed sleepiness drug or end up paying ...

Milvexian’s failure in acute coronary syndrome dampens the outlook for other anticoagulants like it and is the latest in a ...

The deal, one of two multibillion-dollar buyouts from Merck this year, centers around a drug that could become an alternative ...

The European venture firm raised 500 million euros, or about $579 million, for its latest fund, which follows a flurry of ...

Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.